Multiple Myeloma
September 2018 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Multiple Myeloma abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Multiple Myeloma. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Multiple Myeloma. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Multiple Myeloma every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Authors:Aggarwal M, Agrawal N, Yadav N, Verma P, Ahmed R, Mehta P, Kapoor J, Bhurani D
Institution:Department of Hemato-Oncology and Bone Marrow Transplant, Rajiv Gandhi Cancer Institute and Research Centre, Sector - 5, Rohini, New Delhi, 110085, India. bhurani@gmail.com.
Journal:Ann Hematol. 2018 Oct;97(10):1869-1877. doi: 10.1007/s00277-018-3370-1. Epub 2018 May 21.

2:Going the distance: Are we losing patients along the multiple myeloma treatment pathway?
Authors:Terpos E, Suzan F, Goldschmidt H
Institution:Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. Electronic address: eterpos@med.uoa.gr. Center for Tumor Diseases (NCT), Heidelberg, Germany.
Journal:Crit Rev Oncol Hematol. 2018 Jun;126:19-23. doi: 10.1016/j.critrevonc.2018.03.021. Epub 2018 Mar 29.

3:Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
Authors:Katodritou E, Kyrtsonis MC, Delimpasi S, Kyriakou D, Symeonidis A, Spanoudakis E, Vasilopoulos G, Anagnostopoulos A, Kioumi A, Zikos P, Aktypi A, Briasoulis E, Megalakaki A, Repousis P, Adamopoulos I, Gogos D, Kotsopoulou M, Pappa V, Papadaki E, Fotiou D, Nikolaou E, Giannopoulou E, Hatzimichael E, Giannakoulas N, Douka V, Kokoviadou K, Timotheatou D, Terpos E
Institution:Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece. eirinikatodritou@gmail.com.; First Department of Propaedeutic Internal Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.; Department of Hematology and Bone Marrow Transplantation Unit, Evangelismos Hospital, Athens, Greece.; Department of Transfusion Medicine, School of Medicine, University of Thessaly, Larissa, Greece.; Department of Internal Medicine, Division of Hematology, University of Patras Medical School, Patras, Greece.
Journal:Ann Hematol. 2018 Sep;97(9):1671-1682. doi: 10.1007/s00277-018-3361-2. Epub 2018 May 13.

4:Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis.
Authors:Cerrato C, Di Raimondo F, De Paoli L, Spada S, Patriarca F, Crippa C, Mina R, Guglielmelli T, Ben-Yehuda D, Oddolo D, Nozzoli C, Angelucci E, Cascavilla N, Rizzi R, Rocco S, Baldini L, Ponticelli E, Marcatti M, Cangialosi C, Caravita T, Benevolo G, Ria R, Nagler A, Musto P, Tacchetti P, Corradini P, Offidani M, Palumbo A, Petrucci MT, Boccadoro M, Gay F
Institution:Myeloma Unit, Division of Hematology, University of Torino, Azienda-Ospedaliero Universitaria Citta della Salute e della Scienza di Torino, via Genova 3, 10126, Torino, Italy. fgay@cittadellasalute.to.it.; UOC Ematologia, Azienda Policlinico-OVE, University of Catania, Catania, Italy.; Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont and Maggiore Hospital, Novara, Italy.; Dipartimento di Medicina, Universita di Udine, Udine, Italy.; Divisione di Ematologia, Spedali Civili Brescia, Brescia, Italy.
Journal:J Cancer Res Clin Oncol. 2018 Jul;144(7):1357-1366. doi: 10.1007/s00432-018-2641-5. Epub 2018 Apr 19.

5:Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review.
Authors:Mushtaq A, Kapoor V, Latif A, Iftikhar A, Zahid U, McBride A, Abraham I, Riaz IB, Anwer F
Institution:Department of Medicine, Hematology and Oncology, University of Arizona, Tucson, AZ, United States. AZ, United States. AZ, United States. AZ, United States. AZ, United States; College of Public Health, University of Arizona, Tucson, AZ, United States. 85721, United States. United States. AZ, United States. Electronic address: anwerf@email.arizona.edu.
Journal:Crit Rev Oncol Hematol. 2018 May;125:1-11. doi: 10.1016/j.critrevonc.2018.02.008. Epub 2018 Mar 2.

6:Myeloma: Patient accounts of their pathways to diagnosis.
Authors:Howell DA, Hart RI, Smith AG, Macleod U, Patmore R, Cook G, Roman E
Institution:Epidemiology & Cancer Statistics Group, Department of Health Sciences, University of York, York, United Kingdom. of York, York, United Kingdom. of York, York, United Kingdom. Hill Hospital, Cottingham, Hull, United Kingdom. University Hospital, Leeds, United Kingdom. of York, York, United Kingdom.
Journal:PLoS One. 2018 Apr 4;13(4):e0194788. doi: 10.1371/journal.pone.0194788. eCollection 2018.

7:Bortezomib maintenance therapy in transplant-ineligible myeloma patients who plateaued after bortezomib-based induction therapy: a multicenter phase II clinical trial.
Authors:Isoda A, Murayama K, Ito S, Kohara Y, Iino M, Miyazawa Y, Matsumoto M, Handa H, Imai Y, Ishiguro T, Izumita W, Kitano K, Hirabayashi Y, Nakazawa H, Ishida F, Mitsumori T, Kirito K, Chou T, Murakami H
Institution:Department of Hematology, National Hospital Organization Shibukawa Medical Center, 383 Shiroi, Shibukawa, Gunma, 377-0280, Japan. aisoda@sbmc.hosp.go.jp. Iwate, Japan. Yamanashi, Japan. Center, 383 Shiroi, Shibukawa, Gunma, 377-0280, Japan. Center, 383 Shiroi, Shibukawa, Gunma, 377-0280, Japan. Medicine, Gunma, Japan. Center, Nagano, Japan. Center, Nagano, Japan. School of Medicine, Nagano, Japan. Medicine, Nagano, Japan. Sciences, Gunma, Japan.
Journal:Int J Hematol. 2018 Jul;108(1):39-46. doi: 10.1007/s12185-018-2448-9. Epub 2018 Mar 28.

8:Novel Treatments for Multiple Myeloma: What Role Do They Have in Older Adults?
Authors:Mian HS, Wildes TM
Institution:McMaster University, Hamilton, ON, Canada. St Louis, MO, 63110, USA. twildes@wustl.edu.
Journal:Drugs Aging. 2018 Apr;35(4):289-302. doi: 10.1007/s40266-018-0539-1.

9:Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies.
Authors:Chen M, Zhao Y, Xu C, Wang X, Zhang X, Mao B
Institution:Department of Pharmacy, Yangtze University Affiliated Hospital Jingzhou, Hangkong Street 8, Jingzhou, Hubei, 434000, China. mc1220@126.com. Jinlong Street 8, Jingzhou, Hubei, 434000, China. Street 8, Jingzhou, Hubei, 434000, China. Street 8, Jingzhou, Hubei, 434000, China. Street 8, Jingzhou, Hubei, 434000, China. Jingzhou, Hangkong Street 8, Jingzhou, Hubei, 434000, China.
Journal:Ann Hematol. 2018 Jun;97(6):925-944. doi: 10.1007/s00277-018-3284-y. Epub 2018 Mar 2.

10:Proteasome inhibitors for the treatment of multiple myeloma.
Authors:Scalzulli E, Grammatico S, Vozella F, Petrucci MT
Institution:a Hematology, Department of Cellular Biotechnologies and Hematology , "Sapienza" University , Rome , Italy. University , Rome , Italy. University , Rome , Italy. University , Rome , Italy.
Journal:Expert Opin Pharmacother. 2018 Mar;19(4):375-386. doi: 10.1080/14656566.2018.1441287. Epub 2018 Feb 26.

11:Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Authors:Iida S, Wakabayashi M, Tsukasaki K, Miyamoto K, Maruyama D, Yamamoto K, Takatsuka Y, Kusumoto S, Kuroda J, Ando K, Kikukawa Y, Masaki Y, Kobayashi M, Hanamura I, Asai H, Nagai H, Shimada K, Tsukamoto N, Inoue Y, Tobinai K
Institution:Department of Hematology and Oncology, Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG), Nagoya City University Hospital, Nagoya, Japan.; JCOG Data Center/Operations Office, National Cancer Center, Tokyo, Japan.; Department of Hematology, Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG), National Cancer Center Hospital East, Kashiwa, Japan.; Department of Hematology, Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG), National Cancer Center Hospital, Tokyo, Japan.; Department of Hematology and Cell Therapy, Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG), Aichi Cancer Center Hospital, Nagoya, Japan.
Journal:Cancer Sci. 2018 May;109(5):1552-1561. doi: 10.1111/cas.13550. Epub 2018 Apr 17.

12:Improved progression-free and event-free survival in myeloma patients undergoing PBSCH receiving a cyclophosphamide + G-CSF regimen than G-CSF alone.
Authors:Tanimura A, Hirai R, Nakamura M, Takeshita M, Hagiwara S, Miwa A
Institution:Department of Hematology, Tokyo-Kita Medical Center, 4-17-56 Akabanedai, Kita-ku, Tokyo, Japan. akira.tanimura@h3.dion.ne.jp. Tokyo, Japan. Japan. Tokyo, Japan. Tokyo, Japan.
Journal:Int J Hematol. 2018 May;107(5):559-567. doi: 10.1007/s12185-018-2408-4. Epub 2018 Jan 31.

13:Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum.
Authors:Matsumura-Kimoto Y, Kuroda J, Kaneko H, Kamitsuji Y, Fuchida SI, Nakaya A, Shibayama H, Uoshima N, Yokota I, Uchiyama H, Yagi H, Kosugi S, Matsui T, Ishikawa J, Matsuda M, Ohta K, Iida M, Tanaka H, Kobayashi M, Wada K, Shimazaki C, Nomura S, Imada K, Hino M, Matsumura I, Kanakura Y, Takaori-Kondo A
Institution:Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan. junkuro@koto.kpu-m.ac.jp.; Department of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.; Department of Hematology, Matsushita Memorial Hospital, Osaka, Japan.; Department of Hematology, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto, Japan.; First Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
Journal:Int J Hematol. 2018 May;107(5):541-550. doi: 10.1007/s12185-018-2416-4. Epub 2018 Jan 29.

14:Immunopathogenesis and immunotherapy of multiple myeloma.
Authors:Tamura H
Institution:Department of Hematology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. tam@nms.ac.jp.
Journal:Int J Hematol. 2018 Mar;107(3):278-285. doi: 10.1007/s12185-018-2405-7. Epub 2018 Jan 24.

15:Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?
Authors:Leleu X, Gay F, Flament A, Allcott K, Delforge M
Institution:Department of Haematology and CIC Inserm U1082, Hopital La Miletrie, Poitiers, France. xavier.leleu@chu-poitiers.fr. della Salute e della Scienza di Torino, Turin, Italy.
Journal:Ann Hematol. 2018 Mar;97(3):387-400. doi: 10.1007/s00277-017-3191-7. Epub 2017 Dec 27.

16:Living with relapsed myeloma: Symptoms and self-care strategies.
Authors:Cormican O, Dowling M
Institution:The Cancer Clinical Trials Unit, Clinical Research Facility, National University of Ireland Galway, Galway University Hospital, Galway, Ireland.
Journal:J Clin Nurs. 2018 Apr;27(7-8):1713-1721. doi: 10.1111/jocn.14232. Epub 2018 Mar 15.

17:Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma.
Authors:Iida S, Ichinohe T, Shinagawa A, Suzuki K, Takezako N, Aoki M
Institution:Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. iida@med.nagoya-cu.ac.jp. and Medicine, Hiroshima University, Hiroshima, Japan. Japan.
Journal:Int J Hematol. 2018 Apr;107(4):460-467. doi: 10.1007/s12185-017-2390-2. Epub 2017 Dec 19.

18:Falls in older adults with multiple myeloma.
Authors:Wildes TM, Fiala MA
Institution:Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. Medicine, St. Louis, MO, USA.
Journal:Eur J Haematol. 2018 Mar;100(3):273-278. doi: 10.1111/ejh.13009. Epub 2018 Jan 8.

For a FREE PREVIEW of the Medifocus Guidebook on Multiple Myeloma click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Multiple Myeloma click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Multiple Myeloma...
at a Special 20% Discount


Medifocus Guidebook on Multiple Myeloma

Updated: July 4, 2018
203 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Multiple Myeloma is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

MM43178828

Coupon Expires: October 20, 2018



What Our Customers Are Saying...

"The information in your MediFocus Guidebook on Multiple Myeloma was extremely useful. Thank you for providing this service."
K.J.
Milwaukee, Wisconsin


"I purchased the MediFocus Guidebook on Multiple Myeloma for my mother and it was a great help because it helped us to understand more about the disease, the causes, and the treatment options. Although there is no cure, it has helped us cope with the situation and helped us figure out how we can live with the disease."
J.M.
New York, New York


"My oncologist borrowed my copy of the MediFocus Guidebook on Multiple Myeloma and found it very useful in his work. He intends to contact your office."
D.S.
Miami Beach, Florida



  
Medifocus Digest Alert is published by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2018 Medifocus, Inc. All rights reserved.